- 作者：Luisa Soares-Mir ; a ; Carmen Fiuza-Luces ; Alvaro Lassaletta ; Elena Santana-Sosa ; Julio R. Padilla ; Luc¨ªa Fern¨¢ndez-Casanova ; Rosal¨ªa Lorenzo-Gonz¨¢lez ; Luis M. L¨®pez-Mojares ; Margarita P¨¦rez ; Antonio P¨¦rez-Mart¨ªnez ; Alej ; ro Lucia
- 关键词：Randomized controlled trial ; In-hospital exercise ; Children ; Cancer
- 刊名：Contemporary Clinical Trials
- 出版年：2013
- 出版时间：September, 2013
- 年：2013
- 卷：36
- 期：1
- 页码：106-115
- 全文大小：625 K
Background
This randomized controlled trial on Physical Activity in Pediatric Cancer (PAPEC) was designed to assess the impact of an exercise program on pediatric cancer patients undergoing chemotherapy for solid tumors.Methods and design
60 pediatric patients of both sexes, aged 4 to 18 years and undergoing treatment for extracranial primary solid tumors will be recruited for this trial. Each participant will be randomly assigned (with blocking on sex) to either an intervention or control (normal care) group. The intervention group will participate in combined inpatient physical training (aerobic + strength) for the duration of neoadjuvant chemotherapy. The intervention will include 3 weekly 60-70 min exercise sessions in the child's room or in a pediatric gym at the hospital, depending on the child's health state. In both groups, determination of several primary (cardio-respiratory fitness, muscle strength, functional capacity, physical activity levels, body weight and quality of life) and secondary outcomes [immune function and inflammatory profile (blood levels of 47 cytokines)] will be made at the following time points: (i) before the exercise intervention (immediately after diagnosis and before treatment onset); (ii) after the exercise intervention (upon termination of neoadjuvant chemotherapy); and (iii) after a detraining period (2 months after the intervention).
Discussion
The PAPEC trial will provide relevant new information on biological mechanisms and inform on the potential clinical use of exercise during pediatric cancer treatment as a simple way to prevent future long-term treatment effects and improve the general health state of pediatric cancer patients.